Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • 11 hours ago

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.

Business Wire • Feb 23, 2026

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference.

Business Wire • Feb 23, 2026

Down 25%, Should You Buy the Dip on Bristol Myers Squibb?

Multiple core drugs are losing patent protection over the coming years, carving an eventual crater in revenue. Newer, growing drugs should help fill that hole, and Cobenfy is a wild card with huge potential.

The Motley Fool • Feb 21, 2026

Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?

BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.

Zacks Investment Research • Feb 20, 2026

Bristol-Myers: I'm Buying Post Earnings

Bristol-Myers: I'm Buying Post Earnings

Seeking Alpha • Feb 19, 2026

2 Incredibly Cheap Dividend Stocks to Buy Now

A crucial oil and gas infrastructure company has a stock with a 5.9% yield on its dividend. A veteran pharmaceutical giant pays out a dividend yielding a generous 4.2%.

The Motley Fool • Feb 19, 2026

Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength

Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favorite is the 49% year-over-year increase in Breyanzi sales to $392 million in Q4.

Seeking Alpha • Feb 19, 2026

3 Stocks to Buy and Hold for 2026 and Beyond

AbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi. Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.

The Motley Fool • Feb 19, 2026

FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma

FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.

Zacks Investment Research • Feb 18, 2026